ArticleFrontiers in oncology2025
Effective imaging examination evaluation method for surgical pathological complete responds of head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reconsidering Surgical Strategy in the Era of Neoadjuvant Immunotherapy for Head and Neck Cancer.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma: a retrospective analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore an effective method for imaging examinations to evaluate the surgical pathological complete response (PCR) in patients with head and neck squamous cell carcinoma (HNSCC) following neoadjuvant immunochemotherapy (NIC). Methods: HNSCC patients who underwent NIC and subsequent surgery from May 2021 to November 2024 were retrospectively analyzed. All patients underwent imaging examination evaluations, including enhanced computed tomography (CT) and enhanced magnetic resonance (MR) imaging both before and after NIC. The average value of the region of interest (ROI) was extracted from the imaging examinations. Clinical parameter-related data were collected. The paired chi-square test was performed to analyze the differences in complete response (CR) between imaging examinations and pathology according to the response evaluation criteria in solid Tumors version 1.1 (RECISTv1.1). The optimal cutoff values of the adaptive ROI average value were determined using receiver operating characteristic curves (ROC). Binary logistic regression was applied to analyze the relevant clinical factors of PCR. Results: In total, data from 81 patients with enhanced CT and enhanced MR were included in this study. Significant discrepancies in CR were observed between enhanced CT, MRI, and pathology (21.0% Conclusion: Based on RECIST v 1.1, discrepancies in PCR were found between imaging examinations and surgical pathology of HNSCC after NIC. The ROI average value ratio (before/after NIC) was associated with a better PCR, with an enhanced CT ROI average value ratio ≥ 1.18 or the ROI average value ratio ≥ 1.06. Thus, RECIST v1.1 was demonstrated to be an inaccurate assessment method for PCR in HNSCC after NIC. The ROI average value ratio may have good diagnostic efficacy for PCR in HNSCC patients receiving NIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.